Kei Nakashima

Possible Role for Tocilizumab, an Anti–Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia

Katsutoshi Ando, Fumiyuki Takahashi, Shinji Motojima et al. · Journal of Clinical Oncology · 2012 · 124 citations · Full text

Medicine, Hematology, Oncology +13

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies

Ryo Sato, Kosuke Imamura, Shinya Sakata et al. · Journal of Clinical Medicine · 2019 · 89 citations · Full text

Life Sciences, Immunology, Oncology +17

Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection

Nobuhiro Asai, Shinji Motojima, Yoshihiro Ohkuni et al. · Journal of Infection and Chemotherapy · 2012 · 70 citations

Medicine, Clinical Sciences, Infectious Diseases +15

Low-dose trimethoprim-sulfamethoxazole treatment for pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study

Kei Nakashima, Masahiro Aoshima, Tamao Nakashita et al. · Journal of Microbiology Immunology and Infection · 2017 · 56 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +10

Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases

Kentaro Imai, Tanaz Petigara, Melvin A. Kohn et al. · BMJ Open · 2018 · 48 citations · Full text

Veterinary Medicine, Health Sciences, Infectious Diseases +15